Database search strategy
OR "immunization schedule" [mh] ) 558 4 #1 OR #2 OR #3 7.292 5 "9 months" [tiab] 48.137 6 "0 month" [tiab] OR "1 month" [tiab] OR "2 month" [tiab] OR "3 month" [tiab] OR "4 month" [tiab] OR "5 month" [tiab] OR "6 month" [tiab] OR "7 month" [tiab] OR "8 month" [tiab] OR "0 months" [tiab] OR "1 months" [tiab] OR "2 months" [tiab] OR "3 months" [tiab] OR "4 months" [tiab] OR "5 months" [tiab] OR "6 months" [tiab] OR "7 months" [tiab] OR "8 months" [tiab] 7 "1-2 month" [tiab] OR "1-3 month" [tiab] OR "1-4 month" [tiab] OR "1-5 month" [tiab] OR "1-6 month" [tiab] OR "1-7 month" [tiab] OR "1-8 month" [tiab] OR "1-9 month" [tiab] OR "1-10 month" [tiab] OR "1-11 month" [tiab] OR "1-12 month" [tiab] OR "1-13 month" [tiab] OR "1-14 month" [tiab] OR "2-3 month" [tiab] OR "2-4 month" [tiab] OR "2-5 month" [tiab] OR "2-6 month" [tiab] OR "2-7 month" [tiab] OR "2-8 month" [tiab] OR "2-9 month"[tiab] OR "2-10 month" [tiab] OR "2-11 month" [tiab] OR "2-12 month" [tiab] OR "2-13 month" [tiab] OR "2-14 month" [tiab] OR "3-4 month" [tiab] OR "3-5 month" [tiab] OR "3-6 month" [tiab] OR "3-7 month" [tiab] OR "3-8 month" [tiab] OR "3-9 month" [tiab] OR "3-10 month" [tiab] OR "3-11 month" [tiab] OR "3-12 month" [tiab] OR "3-13 month" [tiab] OR "3-14 month" [tiab] 8 "1-2 months" [tiab] OR "1-3 months" [tiab] OR "1-4 months" [tiab] OR "1-5 months"[tiab] OR "1-6 months" [tiab] OR "1-7 months" [tiab] OR "1-8 months" [tiab] OR "1-9 months" [tiab] OR "1-10 months" [tiab] OR "1-11 months" [tiab] OR "1-12 months" [tiab] OR "1-13 months" [tiab] OR "1-14 months" [tiab] OR "2-3 months" [tiab] OR "2-4 months" [tiab] OR "2-5 months" [tiab] OR "2-6 months" [tiab] OR "2-7 months" [tiab] OR "2-8 months" [tiab] OR "2-9 months"[tiab]OR "2-10 months" [tiab] OR "2-11 months" [tiab] OR "2-12 months" [tiab] OR "2-13 months" [tiab] OR "2-14 months" [tiab] OR "3-4 months" [tiab] OR "3-5 months" [tiab] OR "3-6 months" [tiab] OR "3-7 months" [tiab] OR "3-8 months" [tiab] OR "3-9 months" [tiab] OR "3-10 months" [tiab] OR "3-11 months" [tiab] OR "3-12 months" [tiab] OR "3-13 months"[tiab] OR 3-14 months" [tiab] 9 "4-5 month" [tiab] OR "4-6 month" [tiab] OR "4-7 month" [tiab] OR "4-8 month" [tiab] OR "4-9 month" [tiab] OR "4-10 month" [tiab] OR "4-11 month" [tiab] OR "4-12 month" [tiab] OR "4-13 month" [tiab] OR "4-14 month" [tiab] OR "5-6 month" [tiab] OR "5-7 month" [tiab] OR "5-8 month" [tiab] OR "5-9 month"[tiab] OR "5-10 month" [tiab] OR "5-11 month" [tiab] OR "5-12 month" [tiab] OR "5-13 month" [tiab] OR "5-14 month" [tiab] OR "6-7 month" [tiab] OR "6-8 month" [tiab] OR "6-9 month" [tiab] OR "6-10 month" [tiab] OR "6-11 month" [tiab] OR "6-12 month" [tiab] OR "6-13 month" [tiab] OR "6-14 month" [tiab] OR "7-8 month" [tiab] OR "7-9 month" [tiab] OR "7-10 month" [tiab] OR "7-11 month" [tiab] OR "7-12 month" [tiab] OR "7-13 month" [tiab] OR "7-14 month" [tiab] " OR "8-9 month" [tiab] OR "8-10 month" [tiab] OR "8-11 month" [tiab] OR "8-12 month" [tiab] OR "8-13 month" [tiab] OR "8-14 month" [tiab] OR "4-5 months" [tiab] OR "4-6 months" [tiab] OR "4-7 months" [tiab] OR "4-8 months" [tiab] OR "4-9 months" [tiab] OR "4-10 months" [tiab] OR "4-11 months" [tiab] OR "4-12 months"[tiab] OR 4-13 months" [tiab] OR "4-13 months" [tiab] OR "4-14 months" [tiab] OR "5-6 months" [tiab] OR "5-7 months" [tiab] OR "5-8 months" [tiab] OR "5-9 months"[tiab] OR "5-10 months"[tiab] OR "5-11 months" [tiab] OR "5-12 months" [tiab] OR "5-13 months" [tiab] OR "5-14 months" [tiab] OR "6-7 months" [tiab] OR "6-8 months" [tiab] OR "6-9 months"[tiab] OR "6-10 months" [tiab] 'measles vaccine'/mj OR 'measles mumps rubella vaccine'/mj OR 'measles rubella vaccine'/mj OR 'measles mumps vaccine'/mj OR ('measles vaccine'/de AND ('vaccination'/mj OR 'immunization'/mj)) 3.
('measles'/mj OR 'measles virus'/mj) AND ('vaccination'/mj OR 'immunization'/mj) 4.
#1 OR #2 OR #3 5.
'before 9 months':ti,ab OR ('less than' NEAR/4 '9 months'):ti,ab OR (earlier NEAR/4 '9 months'):ti,ab OR 'under 9 months':ti,ab OR 'below 9 months':ti,ab OR ('younger than' NEAR/4 '9 months'):ti,ab 6.
'0 month*':ti,ab OR '1 month*':ti,ab OR '2 month*':ti,ab OR '3 month*':ti,ab OR '4 month*':ti,ab OR '5 month*':ti,ab OR '6 month*':ti,ab OR '7 month*':ti,ab OR '8 month*':ti,ab OR '9 month*':ti,ab OR '1-2 month*':ti,ab OR '1-3 month*':ti,ab OR '1-4 month*':ti,ab OR '1-5 month*':ti,ab OR '1-6 month*':ti,ab OR '1-7 month*':ti,ab OR '1-8 month*':ti,ab OR '1-9 month*':ti,ab OR '2-3 month*':ti,ab OR '2-4 month*':ti,ab OR '2-5 month*':ti,ab OR '2-6 month*':ti,ab OR '2-7 month*':ti,ab OR '2-8 month*':ti,ab OR '2-9 month*':ti,ab 7.
'3-4 month*':ti,ab OR '3-5 month*':ti,ab OR '3-6 month*':ti,ab OR '3-7 month*':ti,ab OR '3-8 month*':ti,ab OR '3-9 month*':ti,ab OR '4-5 month*':ti,ab OR '4-6 month*':ti,ab OR '4-7 month*':ti,ab OR '4-8 month*':ti,ab OR '4-9 month*':ti,ab OR '5-6 month*':ti,ab OR '5-7 month*':ti,ab OR '5-8 month*':ti,ab OR '5-9 month*':ti,ab OR '6-7 month*':ti,ab OR '6-8 month*':ti,ab OR '6-9 month*':ti,ab OR '7-8 month*':ti,ab OR '7-9 month*':ti,ab OR '8-9 month*':ti,ab 8.
'at birth':ti,ab OR newborn*:ti,ab OR (one NEAR/4 month*):ti,ab OR (two NEAR/4 month*):ti,ab OR (three NEAR/4 month*):ti,ab OR (four NEAR/4 month*):ti,ab OR (five NEAR/4 month*):ti,ab OR (six NEAR/4 month*):ti,ab OR (seven NEAR/4 month*):ti,ab OR (eight NEAR/4 month*):ti,ab OR (nine NEAR/4 month*):ti,ab 9.
'first month*':ti,ab OR 'second month*':ti,ab OR 'third month*':ti,ab OR 'fourth month*':ti,ab OR 'fifth month*':ti,ab OR 'first two month*':ti,ab OR 'first three month*':ti,ab OR 'first four month*':ti,ab OR 'first five month*':ti,ab OR 'first six month*':ti,ab OR 'first seven month*':ti,ab OR 'first eight month*':ti,ab OR 'first nine month*':ti,ab OR 'first 2 month*':ti,ab OR 'first 3 month*':ti,ab OR 'first 4 month*':ti,ab OR 'first 5 month*':ti,ab OR 'first 6 month*':ti,ab OR 'first 7 month*':ti,ab OR 'first 8 month*':ti,ab OR 'first 9 month*':ti,ab 10.
(weeks NEAR/4 age):ti,ab 11.
'4.5 months':ti,ab OR ('first dose':ti,ab AND (before NEAR/9 months):ti,ab) 12.
(early NEAR/3 vaccination):ti,ab OR (early NEAR/3 immunization):ti,ab OR (early NEAR/3 immunisation):ti,ab OR (early NEAR/3 mv):ti,ab OR (early NEAR/3 schedule):ti,ab OR 'give earlier':ti,ab OR 'early mv':ti,ab OR 'primary mv':ti,ab OR 'given earlier':ti,ab OR 'early infancy':ti,ab 13.
#4 AND (#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12) 14.
immunogenicity:ti,ab,de OR efficacy:ti,ab,de OR effectiveness:ti,ab,de OR effectivity:ti,ab,de OR 'immunological impact':ti,ab,de OR 'immunogenicity'/de OR 'vaccine immunogenicity'/de OR 'drug efficacy'/de OR 'optimal age':ti OR 'optimum age':ti 15.
'measles cases':ti,ab OR ('measles'/de AND 'incidence'/de) OR ('infant mortality'/de OR 'mortality'/de OR 'death'/de AND 'measles vaccine'/de) OR (measles NEAR/4 (death* OR mortality OR incidence)):ti,ab 16.
'virus antibody'/de OR 'neutralizing antibody'/de OR 'immunoglobulin g'/de OR 'enzymelinked immunosorbent assay'/de OR 'enzyme-linked immunospot assay'/de OR 'hemagglutination inhibition test'/de OR 'virus neutralization'/de OR 'serodiagnosis'/de 17.
'plaque reduction neutralization test*':ti,ab OR prnt:ti,ab OR 'enzyme-linked immunosorbent assay':ti,ab OR 'enzyme-linked immunospot assay':ti,ab OR elisa:ti,ab OR 'hemagglutination inhibition assay':ti,ab OR 'hi assay':ti,ab OR 'complement fixation assay':ti,ab OR 'cf assay':ti,ab OR avidity:ti,ab 18.
('measles vaccine'/de AND 'drug administration'/lnk) OR 'antibody production' OR 'antibody affinity'/de OR 'cellular immunity'/de OR 'lymphocyte activation'/de OR 'cytopathogenic effect'/de OR ('stimulation index':ti,ab AND 't-cell proliferation':ti,ab) 19.
'antibody response*':ti,ab OR 'antibody titer*':ti,ab OR 'antibody titre*':ti,ab OR 'antibody level*':ti,ab OR 'immune response*':ti,ab OR 't-cell response*':ti,ab OR 'cell-mediated immunity':ti,ab OR (humoral NEAR/3 immunity):ti,ab OR 'measles igg':ti,ab OR seroconversion:ti,ab OR 'response to vaccination':ti,ab OR (response NEAR/3 'measles vaccination'):ti,ab 20.
(improve NEAR/3 survival):ti,ab OR (improves NEAR/3 survival):ti,ab OR 'mortality reduction':ti,ab OR 'child mortality':ti,ab OR (prevention NEAR/3 measles):ti,ab OR (risk NEAR/3 measles):ti,ab 21.
reactogenicity:ti,ab,de OR safety:ti,ab,de OR 'adverse events':ti,ab,de OR 'adverse effects':ti,ab,de OR 'side effects':ti,ab,de OR fever:ti,ab,de OR 'local reaction*':ti,ab,de OR convulsion*:ti,ab,de OR purpura:ti,ab,de OR rash:ti,ab,de 22.
'aseptic meningitis':ti,ab OR seizures:ti,ab OR encephalopathy:ti,ab OR anaphylaxis:ti,ab OR hypersensitivity:ti,ab OR 'allergic reaction*':ti,ab OR 'joint pain':ti,ab OR arthropathy:ti,ab OR arthralgia:ti,ab OR arthritis:ti,ab OR cough:ti,ab OR diarrhoea:ti,ab OR diarrhea:ti,ab 23.
'measles vaccine'/de OR 'measles mumps rubella vaccine'/de OR 'measles rubella vaccine'/de OR 'measles mumps vaccine'/de AND ('adverse drug reaction'/lnk OR 'side effect'/lnk) 24.
'measles vaccine'/de OR 'measles mumps rubella vaccine'/de OR 'measles rubella vaccine'/de OR 'measles mumps vaccine'/de AND ('adverse events':de OR 'side effects':de OR 'chemically induced':de OR complications:de OR contraindications:de OR toxicity:de OR poisoning:de OR 'drug effects':de) 25.
(adverse:ti,ab AND (effect*:ti,ab OR event*:ti,ab)) OR 'side effect*':ti,ab OR hypersensitiv*:ti,ab OR sensitiv*:ti,ab OR safe*:ti,ab OR pharmacovigil*:ti,ab 26.
#13 AND (#14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25) 27.
english:la OR dutch:la OR german:la OR french:la OR spanish:la 28.
#26 AND #27 29.
[ TITLE-ABS-KEY((before-9-months) OR ((less-than) W/4 (9-months)) OR (earlier W/4 (9-months)) OR (under-9-months) OR (below-9-months) OR ((younger-than) W/4 (9-months))) 5.
TITLE-ABS-KEY((0-month*) OR (1-month*) OR (2-month*) OR (3-month*) OR (4-month*) OR (5-month*) OR (6-month*) OR (7-month*) OR (8-month*) OR (9-month*) OR (1-2-month*) OR (1-3-month*) OR (1-4-month*) OR (1-5-month*) OR (1-6-month*) OR (1-7-month*) OR (1-8-month*) OR (1-9-month*) OR (2-3-month*) OR (2-4-month*) OR (2-5-month*) OR (2-6-month*) OR (2-7-month*) OR (2-8-month*) OR (2-9-month*)) 6.
TITLE-ABS-KEY ((3-4-month*) OR (3-5-month*) OR (3-6 month*) OR (3-7 month*) OR (3-8 month*) OR (3-9 month*) OR (4-5-month*) OR (4-6-month*) OR (4-7-month*) OR (4-8-month*) OR (4-9-month*) OR (5-6-month*) OR (5-7-month*) OR (5-8-month*) OR (5-9-month*) OR (6-7-month*) OR (6-8-month*) OR (6-9-month*) OR (7-8-month*) OR (7-9-month*) OR (8-9-month*)) 7.
TITLE-ABS-KEY((at-birth) OR newborn* OR (one W/4 month*) OR (two W/4 month*) OR (three W/4 month*) OR (four W/4 month*) OR (five W/4 month*) OR (six W/4 month*) OR (seven W/4 month*) OR (eight W/4 month*)) 8.
TITLE-ABS-KEY((first-month*) OR (second-month*) OR (third-month*) OR (fourthmonth*) OR (fifth-month*) OR (sixth-month*) OR (seventh-month*) OR (eigth-month*) OR (firsttwo-month*) OR (first-three month*) OR (first-four-month*) OR (first-five month*) OR (first-six month*) OR (first-seven month*) OR (first-eight month*) OR (first-nine month*) OR (first-2-month*) OR (first-3-month*) OR (first-4-month*) OR (first-5-month*) OR (first-6-month*) OR (first-7-month*) OR (first-8-month*) OR (first-9-month*)) 9.
TITLE-ABS-KEY(weeks W/4 age) 10.
TITLE-ABS-KEY(4.5-months) OR (TITLE-ABS-KEY(first-dose) AND TITLE-ABS-KEY(before W/9 months)) 11.
TITLE-ABS-KEY((early W/3 vaccination) OR (early W/3 immunization) OR (early W/3 immunisation) OR (early W/3 mv) OR (early W/3 schedule) OR (give-earlier) OR (early-mv) OR (primary-mv) OR (given-earlier) OR (early-infancy)) 12.
#3 AND (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11) 13.
TITLE-ABS-KEY(immunogenic* OR efficacy OR effectiveness OR effectivity OR (immunological-impact) OR immunogenicity) OR TITLE((optimal-age) OR (optimum-age)) 14.
TITLE-ABS-KEY((measles-cases) OR (measles AND incidence) OR ((mortality OR death) AND (measles-vaccin*))) OR TITLE-ABS-KEY(measles W/4 (death* OR mortality OR incidence)) 15.
TITLE-ABS-KEY((plaque-reduction-neutralization-test*) OR prnt OR (enzyme-linkedimmunosorbent-assay) OR (enzyme-linked-immunospot-assay) OR elisa OR (hemagglutinationinhibition assay) OR (hi-assay) OR (complement-fixation-assay) OR (cf-assay) OR avidity OR (virusanitibod*) OR (neutralizing-antibod*) OR (immunogloublin-g) OR (virus-neutralization) OR serodiagnosis) 16.
(KEY(measles vaccine) AND KEY(drug-administration)) OR KEY((antibody-production) OR (antibody-affinity) OR (cellular-immunity) OR (lymphocyte-activation) OR (cytopathogenic-effect) OR ((stimulation-index) AND (t-cell-proliferation))) 17.
TITLE-ABS-KEY((antibody-response*) OR (antibody-titer*) OR (antibody-titre*) OR (antibody-level*) OR (immune-response*) OR (t-cell-response*) OR (cell-mediated-immunity) OR (humoral W/3 immunity) OR (measles-igg) OR seroconversion OR (response-to-vaccination) OR (response W/3 (measles-vaccination))) 18.
TITLE-ABS-KEY((improve W/3 survival) OR (improves W/3 survival) OR (mortalityreduction) OR (child-mortality) OR (prevention W/3 measles) OR (risk W/3 measles)) 19.
TITLE-ABS-KEY(reactogenicity OR safety OR (adverse-events) OR (adverse-effects) OR (side-effects) OR fever OR (local-reaction*) OR convulsion* OR purpura OR rash) 20.
TITLE-ABS-KEY((aseptic-meningitis) OR seizures OR encephalopath* OR anaphylaxis OR hypersensitivity OR (allergic-reaction*) OR (joint-pain) OR arthropathy OR arthralgia OR arthritis OR cough OR diarrhoea OR diarrhea) 21.
KEY((measles-vaccine) OR (measles-mumps-rubella-vaccine) OR (measles-rubella vaccine) OR (measles-mumps-vaccine) ) AND KEY((adverse-drug-reaction*) OR (adverse-effect*) OR (adverse-event*) OR (side-effect*) OR (chemically-induced) OR complications OR contraindications OR toxicity OR poisoning OR (drug-effects)) 22.
TITLE TI,AB((before-9-months) OR ((less-than) W/4 (9-months)) OR (earlier W/4 (9-months)) OR (under-9-months) OR (below-9-months) OR ((younger-than) W/4 (9-months))) 5.
TI,AB((0-month*) OR (1-month*) OR (2-month*) OR (3-month*) OR (4-month*) OR (5-month*) OR (1-2-month*) OR (1-3-month*) OR (1-4-month*) OR (1-5-month*) OR (1-6-month*) OR (1-7-month*) OR (1-8-month*) OR (1-9-month*) OR (2-3-month*) OR (2-4-month*) OR (2-5-month*) OR (2-6-month*) OR (2-7-month*) OR (2-8-month*) OR (2-9-month*)) 6.
TI,AB((3-4-month*) OR (3-5-month*) OR (3-6 month*) OR (3-7 month*) OR (3-8 month*) OR (3-9 month*) OR (4-5-month*) OR (4-6-month*) OR (4-7-month*) OR (4-8-month*) OR (4-9-month*) OR (5-6-month*) OR (5-7-month*) OR (5-8-month*) OR (5-9-month*) OR (6-7-month*) OR (6-8-month*) OR (6-9-month*) OR (7-8-month*) OR (7-9-month*) OR (8-9-month*)) 7.
TI,AB((at-birth) OR newborn* OR (one W/4 month*) OR (two W/4 month*) OR (three W/4 month*) OR (four W/4 month*) OR (five W/4 month*) OR (six W/4 month*) OR (seven W/4 month*) OR (eight W/4 month*) OR (nine W/4 month*)) 8.
TI,AB((first-month*) OR (second-month*) OR (third-month*) OR (fourth-month*) OR (fifth-month*) OR (sixth-month*) OR (seventh-month*) OR (eigth-month*) OR (nine-month*) OR (first-two-month*) OR (first-three month*) OR (first-four-month*) OR (first-five month*) OR (firstsix month*) OR (first-seven month*) OR (first-eight month*) OR (first-nine month*) OR (first-2-month*) OR (first-3-month*) OR (first-4-month*) OR (first-5-month*) OR (first-6-month*) OR (first-7-month*) OR (first-8-month*) OR (first-9-month*)) 9.
TI,AB(weeks W/4 age) 10.
TI,AB(4.5-months) OR (TI,AB,SU(first-dose) AND TI,AB,SU(before W/9 months)) 11.
TI,AB((early W/3 vaccination) OR (early W/3 immunization) OR (early W/3 immunisation) OR (early W/3 mv) OR (early W/3 schedule) OR (give-earlier) OR (early-mv) OR (primary-mv) OR (given-earlier) OR (early-infancy)) 12.
S3 AND (S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11) 13.
TI,AB,SU(immunogenic* OR efficacy OR effectiveness OR effectivity OR (immunologicalimpact) OR immunogenicity) OR TI((optimal-age) OR (optimum-age)) 14.
TI,AB,SU((measles-cases) OR (measles AND incidence) OR ((mortality OR death) AND (measles-vaccin*))) OR TI,AB,SU(measles W/4 (death* OR mortality OR incidence)) 15.
TI,AB,SU((plaque-reduction-neutralization-test*) OR prnt OR (enzyme-linkedimmunosorbent-assay) OR (enzyme-linked-immunospot-assay) OR elisa OR (hemagglutinationinhibition-assay) OR (hi-assay) OR (complement-fixation-assay) OR (cf-assay) OR avidity OR (virusanitibod*) OR (neutralizing-antibod*) OR (immunogloublin-g) OR (virus-neutralization) OR serodiagnosis) 16.
(
SU(measles vaccine) AND SU(drug-administration)) OR SU((antibody-production) OR (antibody-affinity) OR (cellular-immunity) OR (lymphocyte-activation) OR (cytopathogenic-effect) OR ((stimulation-index) AND (t-cell-proliferation))) 17. TI,AB,SU((antibody-response*) OR (antibody-titer*) OR (antibody-titre*) OR (antibodylevel*) OR (immune-response*) OR (t-cell-response*) OR (cell-mediated-immunity) OR (humoral W/3 immunity) OR (measles-igg) OR seroconversion OR (response-to-vaccination) OR (response W/3 (measles-vaccination))) 18. TI,AB,SU((improve W/3 survival) OR (improves W/3 survival) OR (mortality-reduction) OR (child-mortality) OR (prevention W/3 measles) OR (risk W/3 measles)) 19.
TI,AB,SU(reactogenicity OR safety OR (adverse-events) OR (adverse-effects) OR (sideeffects) OR fever OR (local-reaction*) OR convulsion* OR purpura OR rash) 20.
TI,AB,SU((aseptic-meningitis) OR seizures OR encephalopath* OR anaphylaxis OR hypersensitivity OR (allergic-reaction*) OR (joint-pain) OR arthropathy OR arthralgia OR arthritis OR cough OR diarrhoea OR diarrhea) 21.
SU((measles-vaccine) OR (measles-mumps-rubella-vaccine) OR (measles-rubella vaccine) OR (measles-mumps-vaccine)) AND SU((adverse-drug-reaction*) OR (adverse-effect*) OR (adverseevent*) OR (side-effect*) OR (chemically-induced) OR complications OR contraindications OR toxicity OR poisoning OR (drug-effects)) 22.
TI,AB,SU(adverse W/5 (effect* OR event*)) OR TI,AB,SU((side-effect*) OR hypersensitiv* OR sensitiv* OR safe* OR pharmacovigil*) 23. S12 AND (S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22) 24.
LA 
Decision rules for data selection and extraction processes

Types of participants
 Infants <9 months of age receiving their first dose of a MCV.
Types of intervention
 Any currently licensed MCV administered to infants <9 months of age. A currently licensed MCV can be: -Monovalent vaccine: Schwarz, Moraten, Edmonston, Edmonston-Zagreb, Leningrad-16, Shanghai-191, CAM-70, AIK-C and TD97.
Combination vaccine containing various combinations of the above measles strains with other viruses: measles and rubella (MR), measles, mumps and rubella (MMR), measles, mumps, rubella and varicella (MMRV).
Minimum data requirements
 For inclusion in the review, all articles must report age at vaccination. Likewise, for studies on safety, an adverse event following immunization case definition is required, while immunogenicity studies should report the exact vaccine strain and/or potency used and type of laboratory test used.
Exclusion criteria
 Ecological studies, case reports, non-human primate studies, meeting abstracts, editorials, newspaper articles and other forms of popular media were excluded.
 High titre vaccines were excluded from the review, defined as vaccines with a TCID 50 of ≥4.7 or p.f.u. of ≥50,000 (F. Cutts, personal communication). Titres below this cut-off were assumed to be 'standard'. Study results derived from combining MCV with gamma globulin or obtained after intradermal (rather than subcutaneous) administration of MCV were also excluded from the review.
 Failure to meet any one of the above eligibility criteria.
9
Definitions of seroconversion accepted for inclusion in the review Seronegative to seropositive Serum Other Greater than fourfold rise in HAI titre Serum HIA Khanum et al., 1987 Fourfold increase in HI Heel prick HIA Fourfold rise in titre post-vaccination Serum HIA Markowitz et al., 1990 Change from negative (<40miu) pre-vaccination to positive post-vaccination or fourfold increase in level above calculated titre expected 8 or 18 weeks post-vaccination Fingerstick PRNT Ndumbe et al., 1995 Prevaccination <200 mu/ml and postvaccination positive or greater or equal fourfold increase 6 weeks postvaccination Serum ELISA Nkrumah et al., 1998 Seronegative to seropositive, or greater or equal fourfold increase in titre given decay Serum HIA Fourfold increase in titer, adjusted for decay of maternal antibodies Serum PRNT Pongrithsukda et al., 1991 No detectable to detectable antibody Serum PRNT Rogers et al., 1991 Fourfold increase Blood cells ELISA Schatzmayr et al., 1982 Proportion seroconverted in those negative before vaccination (HI<10) Serum HIA Greater or equal than fourfold titre rise Serum PRNT Soula et al., 1991 Lower antibody titer of 1/10 before vaccination and equal or higher post vaccination Serum HIA Stewien et al., 1978 Greater or equal than fourfold titre increase between pre and post vaccination sample Serum HIA Positive 9 month NT and >= 6 month sample Serum PRNT Vidyashankar et al., 2002 No definition given Serum ELISA Whittle et al., 1988 No definition given Other PRNT Wilkins et al., 1979 No definition given Serum HIA Youwang et al., 2001 Negative to positive or >= fourfold rise following re-immunisation Dried blood spots ELISA Characteristics of studies included in the review by outcome 4,5,6,6-7,7,<8, 8-29 EdmonstonZagreb Schatzmayr et al., 1982 Brazil 7,8,9,10,11,1 2-14,15-18,16-24,25 Schwarz , 1982 China 4-6,6,7,7-8,8-12,9-10,11-12 Forest plots for seroconversion Proportion seroconverted, pooled estimates per single ages and age ranges Multivariable meta-regression results for seroconversion in the absence or presence of maternal antibodies 
Definitions of seroconversion not accepted for inclusion in the review
Yes - - - - - -Yes - - - - - - Semba et al., 1995 Indonesia 6 Schwarz Yes - - - - - - Shaoyuan et al.
